


Supplementary Figure S1. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist [9].



Supplementary Table S1. Search strategy

| Databases | Search strategy |
|---------------------|---|
| MEDLINE (PubMed) | ("therapeutic drug monitoring" OR "Drug Dosage Calculations") AND ("software" OR "Drug Therapy, Computer-Assisted" [MeSH Terms] OR "Population pharmacokinetics") |
| Embase | ('therapeutic drug monitoring' OR 'drug dosage calculations') AND ('software'/exp OR 'computer assisted drug therapy'/exp OR 'population pharmacokinetics'/exp) |
| OpenAire | ("therapeutic drug monitoring" AND "software") |
| BASE | ("therapeutic drug monitoring", "drug therapy software", "drug dosage software" AND "pharmacokinetic software") |

Supplementary Table S2. Summary of the articles included in this review

| | Author, year | Country | Objective | Software described |
|----|-------------------------------|-------------|--|--------------------|
| 1 | Hatton et al. 1984 [17] | USA | Compare the accuracy of microcomputer-predicted versus trough serum concentrations during long-term tobramycin therapy | CAPCIL (SIMKIN) |
| 2 | Deci et al. 1985 [18] | USA | Assess the ability of a computer program Simulated Kinetics (SIMKIN) to predict serum theophylline concentrations in ambulatory patients receiving oral theophylline | CAPCIL (SIMKIN) |
| 3 | Leal et al. 1991 [19] | Belgium | Describe a software developed to optimize aminoglycosides monitoring, responding to the demands of most clinical daily situations | PHAR-MONITOR |
| 4 | Messori et al. 1992 [6] | Italy | Present a microcomputer program which analyses multiple-dose pharmacokinetic curves using either a least-squares nonlinear analysis or a Bayesian fit | PKRD |
| 5 | Proost et al. 1992 [20] | Netherlands | Describe the main features of MW/PHARM and exemplify with gentamicin and phenytoin | MWPHARM |
| 6 | Gill et al. 1992 [21] | USA | Report the use of a new method to determine patient population pharmacokinetic parameters compared to a more traditional approach | NPEM (USC*PACK) |
| 7 | McMichael et al. 1993 [22] | USA | Validate an intelligent dosing system (IDS) used to guide all doses to prospectively achieve the target concentration range specified in autoimmune disorders | IDS |
| 8 | Ismail et al. 1993 [23] | Malaysia | Estimate individual and population pharmacokinetics for carbamazepine in Malaysian epileptic patients using the OPT computer program | OPT |
| 9 | Lacarelle et al. 1994 [24] | France | Validate a new software package in routine clinical practice for amikacin and theophylline | PKS |
| 10 | Jerling, 1996 [25] | Sweden | Demonstrate how the population approach can be used to evaluate different kinetic and dynamic aspects of a drug and to give some suggestions for how to utilize the results in clinical practice | NPML |
| 11 | Falcao et al. | Portugal | Study the kinetic behaviour of theophylline administered concomitantly with methylprednisolone and auranofin, using PKS | PKS and CAPCIL |

| | | | | |
|----|----------------------------|-------------|---|--|
| | 2000 [26] | | and CAPCIL for the kinetic analysis | |
| 12 | Wright et al. 2011 [27] | New Zealand | Develop a Bayesian dose individualisation tool for warfarin and incorporate it into the freely available software TCIWorks for use in the clinic | TCIWorks |
| 13 | Neely et al. 2012 [28] | USA | Describe “Pmetrics”, a newly software package and test the theoretical advantage of the nonparametric approach to accurately characterize subpopulations and outliers by estimating population and individual pharmacokinetic parameters in a simulated data set with the parametric IT2B and nonparametric NPAG algorithms in Pmetrics | NPAG and IT2B |
| 14 | Fuchs et al. 2013 [7] | Switzerland | Assess and compare computer tools designed to support TDM clinical activities | JPKD, TDM for R, RxKinetics (Antibiotic Kinetics, APK and Kinetics), Kinetidex, T.D.M.S. 2000, DataKineticsTM, RADKinetics, MM-USC*PACK, TCIWorks, MwPharm |
| 15 | Felton et al. 2014 [29] | UK | Establish a population PK model for piperacillin in critically ill patients and analyze the performance of the model in the dose optimization software program BestDose | BestDose |
| 16 | Dubovitska et al. 2017 [2] | Switzerland | Present TUCUXI – an intelligent system for TDM and discuss ethical issues related to the use of an automated decision support system in clinical practice | TUCUXI |
| 17 | Owens et al. 2018 [14] | USA | Explain advances in technology that allow clinicians to apply PK-PD to optimize the agents and dosing regimens selected for the treatment of hospitalized patients with infection | PK-PD Compass, TDMx, DoseMeRx and InsightRx |
| 18 | Nugroho et al. 2019 [30] | Indonesia | Simulate the capability of Monolix, NONMEM, and WinBUGS-PKBUGS to analyze very sparse Cp-time data after an intravenous bolus drug administration and to estimate the minimum number of Cp-time data required for an adequate analysis | Monolix, NONMEM, and WinBUGS-PKBUGS |
| 19 | Okour, 2020 [31] | USA | Present DosePredict, a Shiny-based graphical user interface software that can be used for | DosePredict |

| | | | | |
|----|--------------------------------|----------------|--|--|
| | | | the conduct of dose predictions | |
| 20 | Kantasiripitak et al. 2020 [1] | Belgium | Identifying the requirements for and evaluating the performance of the currently available model-informed precision dosing software tools | DoseMeRx, InsightRX Nova, MwPharm++, PrecisePK, Kinetics, BestDose, ID-ODS, NextDose, Tucuxi, Autokinetics, TDMx |
| 21 | Porubán et al. 2020 [32] | Czech Republic | Compare the usefulness of DOS and Windows version (WIN) of the MwPharm, and their prediction quality in TDM of digoxin | MwPharm |
| 22 | Ryan et al. 2021 [33] | Australia | Evaluate amikacin prescribing and TDM practices, and determine the suitability of the amikacin model incorporated into the DoseMeRx® software as a replacement for the previously available software (Abbottbase®) | Abbottbase, DoseMeRx |
| 23 | Dave et al. 2021 [34] | Germany | Compare measured Infliximab concentrations in the laboratory with values predicted by iDose dashboard system and report its efficacy in managing patients not responding to conventional dosing schedule | iDose |
| 24 | Sturkenboom et al. 2021 [35] | Australia | Provide an update on the pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs and to show how population pharmacokinetics and Bayesian dose adjustment can be used to optimize treatment. | NONMEM, Pmetrics, ADAPT, MwPharm, Monolix, Phoenix, and NPEM2 |
| 25 | Heitzmann et al. 2022 [36] | France | Implement and compare two pharmacometric tools for daptomycin TDM and precision dosing | BestDose and TUCUXI |

Supplementary Table S3. Software tools for modelling or research

| Function/use | Software tool |
|--------------|--|
| Modelling | ADAPT, IT2B, NPAG, NPML, Monolix, PhoenixNLME, WinBUGS-PKBUGS, WinNonlin |
| Research | DosePredict |